# CAR-T cell therapy: Science

Source page: https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-science/

#### Principles

The science it rests on, with why each principle matters to it
 Relies on

- [Acquired immunity and antibodies](https://www.materialinsights.org/science/acquired_immunity/) Killer T cells normally destroy a cell only when they recognise both a foreign marker and the body's own molecules, as Doherty and Zinkernagel found ^[6]; a CAR gives them antibody-type targeting instead ^[2].
- [The genetic code](https://www.materialinsights.org/science/genetic_code/) The T cells are given a new gene, and their own machinery reads it to build the receptor ^[3].

as of 2026-11-11

#### Discoveries

The discoveries that made it possible: when, by whom and what was found

| Year | Who | What |
|---|---|---|
| 1973 | Peter Doherty and Rolf Zinkernagel | Killer T cells must recognise both a virus and the body's own molecules to kill an infected cell (work of 1973 to 1975) ^[6] |
| 1975 | Georges Köhler and César Milstein | The hybridoma technique for making monoclonal antibodies ^[7] |
| 1989 | Gideon Gross, Tova Waks and Zelig Eshhar | Chimeric receptors that give T cells antibody-type targeting ^[2] |

as of 2026-11-11

#### The science explained

The science behind it explained for a curious reader

T cells are the immune system's security guards. Each carries receptors that check other cells for signs of trouble, but they only react when the trouble is shown to them in a particular way, alongside the body's own molecules ^[6]. Many cancer cells slip past. Antibodies work differently: they can grab a chosen marker on any cell directly, and since 1975 scientists have been able to make antibodies to order ^[7]. A chimeric antigen receptor brings antibody-type targeting to a T cell ^[2]. A T cell carrying it can recognise a marker such as CD19 on a leukaemia cell, switch on, kill the cell and then copy itself, so the dose keeps working inside the body ^[4].

as of 2026-11-11

#### Sources

1. [Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity](https://www.migal.org.il/en/node/5851) Proceedings of the National Academy of Sciences (Gross, Waks, Eshhar), record at MIGAL, 1989
2. [FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US](https://www.pharmtech.com/view/fda-approves-novartis-car-t-drug-first-gene-therapy-approval-us-0) Pharmaceutical Technology, 2017
3. [FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release)](https://pennmedicine.org/news/news-releases/2017/august/fda-approves-personalized-cellular-therapy-for-advanced-leukemia) Penn Medicine, 2017
4. [The Nobel Prize in Physiology or Medicine 1996 - Press release](https://nobelprize.org/prizes/medicine/1996/press-release) Nobel Assembly at Karolinska Institutet, 1996
5. [The Nobel Prize in Physiology or Medicine 1984: press release](https://nobelprize.org/prizes/medicine/1984/press-release) Nobel Assembly at Karolinska Institutet (nobelprize.org)

## Other sections

- [Summary](https://www.materialinsights.org/technologies/car_t_cell_therapy/index.md)
- [Overview](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-overview/index.md)
- [Evolution](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-evolution/index.md)
- [Materials](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-industries/index.md)
